Dr. Wyatt’s research is focused on metastatic genitourinary cancers, including prostate and bladder cancer. To enable genomic profiling of these cancers, his team has pioneered methods for circulating tumour DNA analysis of prostate cancer from minimally invasive blood samples,  developed targeted sequencing approaches, built custom bioinformatic software and amassed important clinical data from men with metastatic prostate cancer, enabling comparison of genomic alterations with treatment outcomes.

Dr. Wyatt designed the circulating tumour DNA screening strategy and directs the molecular tumour board for the Canadian Cancer Trials Group (CCTG) Phase II precision oncology umbrella trial for metastatic prostate cancer. The Canada-wide trial matches patients with treatments based on analysis of their circulating tumour DNA and has enrolled more than 350 patients to date. His laboratory is also working to bring his research to the clinic by creating a panel-based circulating tumour DNA test that could be used as part of routine clinical practice.

Learn more about Dr. Wyatt’s research here.

Selected Publications

Evolution of castration-resistant prostate cancer in ctDNA during sequential androgen receptor pathway inhibition

Clinical Cancer Research
Matti Annala, Sinja Taavitsainen, Daniel J Khalaf, Gillian Vandekerkhove, Kevin Beja, Joonatan Sipola, Evan W Warner, Cameron Herberts, Amanda Wong, Simon Fu, Daygen L Finch, Conrad D Oja, Joanna Vergidis, Muhammad Zulfiqar, Bernhard J Eigl, Christian K Kollmansberger, Matti Nykter, Martin E Gleave, Kim N Chi, Alexander W Wyatt

Cross-resistance renders multiple lines of androgen receptor (AR) signaling inhibitors increasingly futile in metastatic castration-resistant prostate cancer (mCRPC). We sought to determine acquired genomic contributors to cross-resistance.

Back to top